Pharmacist

ROWASA Kit* Includes:

  • ROWASA®(mesalamine) Rectal Suspension Enema 4.0g/60mL for the relief of flare symptoms associated with active mild to moderate distal ulcerative colitis (UC), proctosigmoiditis, or ulcerative proctitis.
  • Complimentary personal cleansing wipe (with no price increase) that leaves UC patients clean and fresh.
  • Exclusive Bottle: FDA study confirmed the ROWASA bottle offers significant patient benefits over generic bottles including it is easier to squeeze and has softer delivery system.1
  • eVoucher™ program automatically reduces patient co-pay**

Key Features:

  • Reduces rectal bleeding in as little as 3 days2 (p<0.0001)
  • Relief of other common flare symptoms – including diarrhea and abdominal pain3
  • Complements other therapies to quickly address flares4

Availability: ROWASA Kit* is available by prescription only in the following configurations:

  • NDC 68220-066-03
    Unit of 28 Bottles + 28 Wipes
  • NDC 68220-066-05
    Unit of 7 Bottles + 7 Wipes

Common wholesaler order numbers are (if you do not see yours please contact us):

Wholesaler

Order #  
NDC:68220-066-03
ROWASA Kit 28 Pack

Order #  
NDC:68220-066-05 
ROWASA Kit 7 Pack

Amerisource Bergen

345579

344184

Bellco

285966

285958

Cardinal Health

4106423

4106407

HD Smith

2170140

2170157

Kinray

764928

159905

McKesson

1893833

1843275

McQueary

793817

875384

NC Mutual

 691-436

 691-428

Rochester Drug

 

10193118

Smith

27-1049

26-9746

Questions:  1-888-317-0001, x10150, rowasa@alavenpharm.com

1 D. L. Walsh , R. J. Schroeder , S. F. Stewart , CDRH, FDA, Rockville, MD. Mechanical performance of generic and proprietary enema bottles. 12th Annual FDA Science Forum, April 18-20, 2006. Category: M. Engineering and Physics, M-07.
2 Sutherland LR, Martin F, Greer S, et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894-1898.
3 ROWASA® Prescribing Information  08/08
4 Safdi M. DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-1871

* Wipe is optional and not a required part of treatment.
**Visit http://evoucherrx.relayhealth.com/storelookup/ for a listing of participating pharmacies. eVoucher is a trademark of RelayHealth and/or its affiliates.



 
Home  |  Stay Up-to-Date  |  About Alaven  |  Privacy Policy  |  Contact Us

Important Safety Information
Contraindications: ROWASA® (mesalamine) Rectal Suspension Enema is contraindicated for patients known to have hypersensitivity to the drug or any component of this medication.
Warning: ROWASA® (mesalamine) Rectal Suspension Enema contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low.
Precautions: Mesalamine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. Caution should be exercised when mesalamine is initially used in patients known to be allergic to sulfasalazine.
Adverse Reactions: ROWASA® (mesalamine) Rectal Suspension Enema is usually well tolerated. Most adverse effects have been mild and transient. The most frequently reported adverse events include abdominal cramps, headache, gas, nausea, flu, fatigue, fever and rash.

The current formulation of ROWASA (mesalamine) is approved by the FDA for the treatment of mild to moderate distal ulcerative colitis, proctosigmoiditis, or ulcerative proctitis and is manufactured and marketed by Alaven Pharmaceutical. Click here for full prescribing information >>
© 2008 Alaven® Pharmaceutical LLC, Marietta, GA. All rights reserved.
ROWASA® is a registered trademark of Alaven® Pharmaceutical LLC.